EyePoint Pharmaceuticals
EYPT
EYPT
138 hedge funds and large institutions have $1.18B invested in EyePoint Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
47.74% more ownership
Funds ownership: 96.37% → 144.11% (+48%)
41% more funds holding
Funds holding: 98 → 138 (+40)
33% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 30
Holders
138
Holding in Top 10
5
Calls
$60.4M
Puts
$35.2M
Top Buyers
| 1 | +$65.6M | |
| 2 | +$63.1M | |
| 3 | +$57.8M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$36M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$35.3M |
Top Sellers
| 1 | -$26.9M | |
| 2 | -$26.6M | |
| 3 | -$13.5M | |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$5.15M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$3.7M |